HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 362 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Celebrating 10 years of partnership with NIVEA Sun October 14, 2022 FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... May 13, 2026 Survivor’s Lucky Chance Encounter with Her Old Surgeon Leads to an... August 6, 2021 Intensive care nurse describes his experience of female-centred care after breast... February 7, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation Under Exceptional Circumstances for Moxetumomab... For Women With Dense Breasts, An MRI May Be A Better... “Solid Stress” Keeps Immune System from Killing Off Cancer Cells in... Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and...
